Abdul Kazi, MD
Ophthalmology · Anniston, ALNPI 1790856144
Payments from drug & device makers
Across 307 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$553
- Genentech USA, Inc.$456
- Eyevance Pharmaceuticals LLC$388
- Mallinckrodt Hospital Products Inc.$289
- Novartis$278
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,17999%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $1,640 |
| Alcon | 28 | $553 |
| Genentech USA, Inc. | 24 | $456 |
| Eyevance Pharmaceuticals LLC | 21 | $388 |
| Mallinckrodt Hospital Products Inc. | 10 | $289 |
| Novartis | 13 | $278 |
| Oyster Point Pharma, Inc. | 10 | $185 |
| Harrow Eye, LLC | 7 | $141 |
| NEW World Medical,inc. | 7 | $119 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $117 |
| Astellas Pharma US Inc | 6 | $109 |
| Bausch & Lomb Americas Inc. | 6 | $105 |
| Tarsus Pharmaceuticals, Inc. | 6 | $96 |
| Ocular Therapeutix, Inc. | 4 | $93 |
| Aerie Pharmaceuticals, Inc. | 5 | $87 |
| Apellis Pharmaceuticals, Inc. | 3 | $78 |
| Sight Sciences, Inc. | 4 | $70 |
| Ivantis, Inc | 4 | $59 |
| Amgen | 4 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Kala Pharmaceuticals, Inc. | 2 | $48 |
| Glaukos Corporation | 2 | $33 |
| Dompe US, Inc. | 2 | $30 |
| Rxsight Inc | 1 | $24 |
| Akorn, Inc. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $16 |
| Alimera Sciences, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Eyepoint US, Inc. | 1 | $11 |
How this compares
$5,217 in reported general payments places this provider in the 75th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 329 | $391,778 |
| Cyclosporine | 111 | $57,422 |
| TyrvayaVarenicline Tartrate | 68 | $54,274 |
| XiidraLifitegrast | 66 | $45,463 |
| LumiganBimatoprost | 92 | $32,039 |
| ZyletTobramycin/Lotepred Etab | 88 | $28,913 |
| RocklatanNetarsudil Mesylat/Latanoprost | 58 | $22,346 |
| Alphagan PBrimonidine Tartrate | 80 | $21,037 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 85 | $17,743 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $11,838 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 117 | $11,542 |
| RhopressaNetarsudil Mesylate | 28 | $10,065 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 208 | $9,942 |
| MoxifloxacinMoxifloxacin Hcl | 277 | $9,908 |
| EysuvisLoteprednol Etabonate | 18 | $8,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan, Restasis Multidose | $1,640 | $464,349555 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $185 | $54,27468 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $105 | $52,97989 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $87 | $32,41186 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Loteprednol Etabonate | $117 | $31,158105 claims |
| AlconSimbrinza | $553 | $17,74385 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $48 | $8,82318 claims |
| Akorn, Inc.Azasite | $18 | $2,68311 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $388 | $2,47611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Anniston
- Kent KeysAnniston$6K
- Sebastian HeersinkDothan$3.9M
- Bret FisherHomewood$821K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$254K
- Ann Arciniegas-BernalBirmingham$142K
- Harsha SenDothan$140K
- John CoxHuntsville$118K
- Young ChoiVestavia$76K
- Kristin BainsBirmingham$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.